At the time of writing, Protalix BioTherapeutics Inc [PLX] stock is trading at $1.5, up 4.90%. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The PLX shares have gain 1.35% over the last week, with a monthly amount glided 4.90%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Protalix BioTherapeutics Inc [AMEX: PLX] stock has seen the most recent analyst activity on June 08, 2020, when H.C. Wainwright reiterated its Buy rating and also boosted its price target to $11 from $3. Previously, Rodman & Renshaw reaffirmed its Buy rating on April 17, 2017, and elevated its price target to $5. On April 04, 2016, Rodman & Renshaw initiated with a Buy rating and assigned a price target of $3.50 on the stock. Jefferies upgraded its rating to a Buy and increased its price target to $2.60 on April 23, 2015. R. F. Lafferty reiterated its recommendation of a Buy and reduced its price target to $5 on November 12, 2014. R. F. Lafferty started tracking with a Buy rating for this stock on January 24, 2014, and assigned it a price target of $8. In a note dated May 02, 2012, Oppenheimer reiterated an Outperform rating on this stock and boosted its target price from $9 to $11.
For the past year, the stock price of Protalix BioTherapeutics Inc fluctuated between $0.82 and $3.10. Protalix BioTherapeutics Inc [AMEX: PLX] shares were valued at $1.5 at the most recent close of the market.
Analyzing the PLX fundamentals
According to Protalix BioTherapeutics Inc [AMEX:PLX], the company’s sales were 59.76M for trailing twelve months, which represents an 169.82% jump. Gross Profit Margin for this corporation currently stands at 0.5% with Operating Profit Margin at 0.08%, Pretax Profit Margin comes in at 0.09%, and Net Profit Margin reading is 0.07%. To continue investigating profitability, this company’s Return on Assets is posted at 0.05, Equity is 0.1 and Total Capital is 0.09. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.12.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
It is important to note that Protalix BioTherapeutics Inc [AMEX:PLX] has a current ratio of 2.49. In addition, the Quick Ratio stands at 1.69 and the Cash Ratio stands at 0.8. Considering the valuation of this stock, the price to sales ratio is 2.00, the price to book ratio is 2.59 and price to earnings (TTM) ratio is 35.71.
